No Data
No Data
GF Securities: The price of active pharmaceutical ingredients stabilizes at the bottom, with a slight increase in double bond prices.
In 2024, with relatively low inventory levels, some downstream formulation companies began to replenish their stockpiles. In addition, the continuous release of new active pharmaceutical ingredients after the expiration of patents, the sector is in a bottoming out stable recovery state.
Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Price Is Right But Growth Is Lacking
Zhejiang Ausun Pharmaceutical 2024 Interim Report
Summary of the 2024 semi-annual report of Zhejiang Ausun Pharmaceutical.
Zhejiang Ausun Pharmaceutical (603229.SH) released its half-year performance, with a net income of 0.18 billion yuan, an increase of 12.26% year-on-year.
Zhejiang Ausun Pharmaceutical (603229.SH) released its 2024 interim report, with a revenue of 4...
Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Largest Shareholder, CEO Zhiguo Zheng Sees Holdings Value Fall by 6.7% Following Recent Drop
No Data
No Data